Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Twitter
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > Disadvantaged neighbourhoods may contribute to racial disparities in risk of aggressive prostate cancer
  • News

Disadvantaged neighbourhoods may contribute to racial disparities in risk of aggressive prostate cancer

  • 1 August 2024
  • Janet Fricker
Disadvantaged neighbourhoods may contribute to racial disparities in risk of aggressive prostate cancer
Total
0
Shares
0
0
0
0
0

Men with prostate cancer living in disadvantaged neighbourhoods show significantly higher activity of stress-related genes than those living in other neighbourhoods. The observational study, published in JAMA Network Open, 12 July, found that neighbourhood disadvantage was positively associated with the expression of a number of stress-related genes, some of which are proinflammatory and could contribute to making tumours more aggressive.

“Our study findings suggest that neighborhood disadvantage adversely impacts stress-related genetic pathways in the body. We believe that this may in turn increase an individual’s risk of aggressive prostate cancer,” study senior author Kathryn Hughes Barry, tells Cancerworld. “Since African American individuals are more likely to reside in disadvantaged areas than White individuals,” she adds, “this may contribute in part to the higher risk of aggressive prostate cancer among African American men.” Barry, who is Assistant Professor at the University of Maryland School of Medicine and a cancer epidemiologist at the Greenebaum Comprehensive Cancer Center, believes that understanding the mechanisms that contribute to an individual’s risk of aggressive prostate cancer could ultimately lead to interventions that lower the burden of aggressive disease and related racial disparities.

In African American men the incidence of prostate cancer is more than 1.5 times higher than for White men in the United States, and mortality twice as high. As well as being more likely to be diagnosed with advanced prostate cancer (due to reduced access to health care and screening), African American men are more prone to aggressive forms of the disease, which are more likely to be fatal. Increasing literature supports the concept of neighbourhood socioeconomic deprivation, which disproportionately affects African American individuals, being associated with a higher likelihood of being diagnosed with an advanced or aggressive prostate cancer. Evidence for the link between living in stressful neighbourhoods and cancer was reviewed in a 2022 Cancerworld feature.

For the current study, Barry and colleagues hypothesised that neighbourhood disadvantage would affect the expression of stress-related genes, which in turn would contribute to an increased risk of aggressive prostate cancer.

The cross-sectional study included 218 men with prostate cancer, of whom 168 (77%) were African American and 50 (23%) White, who had undergone radical prostatectomy at the University of Maryland Medical Center between August 1992 and January 2021. To be eligible, subjects needed to have RNA expression data from prostate tumour tissue and a valid residential address at time of diagnosis.

RNA expression data was obtained using an assay called the Human Clariom D array, which measures the activity level of genes and transcripts throughout the genome (138,745 transcripts). For the current study, the team focused on two different sets of genes, for a total of 105 stress-related genes. The first set encompassed genes in the Conserved Transcriptional Response to Adversity (CTRA), while the second set included stress-related signalling genes (genes in the serotoninergic, adrenergic, glucocorticoid, dopaminergic, and muscarinic systems). “Many of the genes that we studied have been previously linked with prostate cancer risk, progression, or death,” explains Joseph Boyle, the first author of the study, from the Massey Comprehensive Cancer Center at Virginia Commonwealth University.

Neighbourhoods where patients lived at time of diagnosis were evaluated using two indexes of neighbourhood deprivation (Area Deprivation Index and Neighbourhood Deprivation Index), taking into account neighborhood-level income, education, employment and housing quality. The team also looked at racial segregation (using the Racial Isolation Index) and historical ‘redlining’, where certain neighbourhoods in the past were systematically denied mortgage applications or refinancing. “While the redlining occurred many years ago, this led to long-term disinvestment and disadvantage that has been linked with worse health outcomes in the present day, including cancer outcomes,” explains Barry.

Results showed that African American participants experienced greater neighbourhood disadvantage than White participants. The median Area Deprivation Index score was 115 for African American men vs 92 for White men, while the median Racial Isolation Index was 0.68 for African American men vs 0.11 for White men.

The Area Deprivation Index was found to be associated with higher RNA expression for 11 stress-related genes – HTR6 (P<0.001, serotonin pathway), HTR4 (P=0.003, serotonin pathway), HTR3D (P=0.006, serotonin pathway), IFIT5 (P=0.009, type I interferon responses), IFIT2 (P=0.009, type I interferon responses), CXCL8 (P=0.01, proinflammatory), FOSL2 (P=0.02, proinflammatory), IL1β (P=0.02, proinflammatory), MX2 (P=0.03, type I interferon responses), IFI44L (P=0.04, type I interferon responses), and FOS (P=0.05, proinflammatory).

Several of the genes (HTR6, IFIT2, MX2, and FOS) were associated with more than one measure of neighbourhood disadvantage. After multiple-comparison adjustments, the association between the Area Deprivation Index and HTR6, a gene in the serotonin pathway, remained statistically significant (β=0.003, SE=0.001; P<0.001; Benjamini-Hochberg q-value=0.01).

HTR6 encodes a receptor that is part of the 7-transmembrane G protein-coupled receptor family, and plays a role in activating the cyclic AMP-dependent signalling pathway. “This receptor is hypothesized to be involved in regulating cholinergic neuronal transmission. Among other roles, the cholinergic system is important in regulating immune response, and its dysregulation is thought to contribute to some inflammatory and autoimmune conditions. There is also evidence that expression of HTR genes may be associated with lethal prostate cancer,” write the authors.

It was also noteworthy that the investigators observed positive associations between neighbourhood disadvantage and several proinflammatory genes (CXCL8, FOSL2, IL1B, FOS, and PTGS1). “An individual’s RNA levels can change in response to stress, and we and others hypothesise that resulting biologic effects, such as increased inflammation, may contribute to an increased risk of aggressive prostate cancer,” says Barry.

Next, the team plans to conduct a larger follow-up study including men from other regions across the US, to assess whether findings will be replicated and to increase their generalisability. “One of the limitations of our current study is that we only had address information at diagnosis for the study participants. In our future work, we aim to gather additional residential information, so we can investigate the role of neighbourhood disadvantage over an individual’s lifetime,” says Barry.

In the long term, one potential clinical application of this field of research could be that information on an individual’s RNA expression profile could be harnessed for precision medicine. For example, says Barry, RNA expression profiles could be used to identify healthy men at higher risk of developing aggressive disease who would benefit from more frequent prostate screening, or to identify patients diagnosed with prostate cancer who are more likely to progress and who might benefit from different clinical management. “It’s an interesting idea that, in the future, therapeutic interventions could be developed to reduce elevated expression of these genes, but much more work would need to be done – including experimental studies and clinical trials – before considering this possibility,” says Barry.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • African Americans
  • aggressive prostate cancer
  • disadvantaged neighbourhoods
  • proinflammatory environment
  • prostate cancer
  • race disparities
  • socioeconomic deprivation
  • stress related genes
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • News

Exercise boosts anti-tumour immune cells in people with breast cancer

  • 29 July 2024
  • Janet Fricker
View Post
Next Article
  • News

Endometriosis: impact on ovarian cancer varies by subtype

  • 28 August 2024
  • Janet Fricker
View Post
You May Also Like
View Post
  • News

Key link identified in mechanism promoting lung metastases from breast cancer

  • Janet Fricker
  • 17 February 2025
View Post
  • News

OncoDaily Acquires CancerWorld: A New Era in Oncology Media

  • Christopher Greenberg
  • 22 January 2025
View Post
  • News

Second-generation BTK inhibitor shows promise as fixed-duration therapy in CLL

  • Janet Fricker
  • 18 December 2024
View Post
  • News

New evidence can help inform decisions on managing early-onset breast cancer linked to BRCA mutations

  • Janet Fricker
  • 18 December 2024
View Post
  • News

Gut microbiota influence effectiveness of tamoxifen in breast cancer

  • Janet Fricker
  • 6 December 2024
View Post
  • News

Radiotherapy prior to immunotherapy is the best treatment sequence for melanoma related brain metastases

  • Janet Fricker
  • 6 December 2024
View Post
  • News

Study helps solve the puzzle of checkpoint inhibitor myocarditis

  • Janet Fricker
  • 22 November 2024
View Post
  • News

Smoking cessation fundamental to first-line cancer care

  • Janet Fricker
  • 21 November 2024
search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Key link identified in mechanism promoting lung metastases from breast cancer
    • 17 February 2025
  • OncoDaily Acquires CancerWorld: A New Era in Oncology Media
    • 22 January 2025
  • Second-generation BTK inhibitor shows promise as fixed-duration therapy in CLL
    • 18 December 2024
  • New evidence can help inform decisions on managing early-onset breast cancer linked to BRCA mutations
    • 18 December 2024
  • Gut microbiota influence effectiveness of tamoxifen in breast cancer
    • 6 December 2024
Article
  • China’s integrated cancer care guidelines ‘reflect self-confidence’ in the field of oncology
    • 15 February 2025
  • Europe’s cancer agenda: how we keep it a priority in changing times
    • 20 December 2024
  • Humour: an essential tool in cancer care and communication
    • 18 December 2024
Social

Would you follow us ?

Contents
  • Stella Kyriakides: using her voice to improve health in Europe
    • 22 November 2024
  • Bulgarian oncologist Assia Konsoulova
    Assia Konsoulova: improving Bulgaria’s cancer system one oasis at a time
    • 8 November 2024
  • Mohit Singh and his mother Amrita: they are the protagonists of a long and ultimately unsuccessful journey across India in search of cures for her cancer
    ‘I feel guilty sometimes’: a young carer reflects on three years of a losing battle to save his mum
    • 24 October 2024
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.